Author:
Hong Shaodong,Tan Min,Wang Shouzheng,Luo Shengyuan,Chen Yue,Zhang Li
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference59 articles.
1. Ahn JS et al (2013) A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer 82:455–460
2. Aisner J, Manola JB, Dakhil SR, Stella PJ, Sovak MA, Schiller JH (2013) Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501). J Thorac Oncol 8:1075–1083
3. Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA (2008) Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 26:4047–4048
4. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592–603
5. Boutsikou E et al (2013) Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. OncoTargets Ther 6:125–134. doi: 10.2147/OTT.S42245
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献